Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
<p>Abstract</p> <p>Background</p> <p>Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function <it>in vivo</it>....
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-07-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/11/308 |
| _version_ | 1811279751848919040 |
|---|---|
| author | Raphael Benjamin J Singh Rakesh K Ritz Anna Kim Kyu K Miller Daniel H Hillenmeyer Sara Fischer Andrew Stuckey Ashley Brard Laurent Brodsky Alexander S |
| author_facet | Raphael Benjamin J Singh Rakesh K Ritz Anna Kim Kyu K Miller Daniel H Hillenmeyer Sara Fischer Andrew Stuckey Ashley Brard Laurent Brodsky Alexander S |
| author_sort | Raphael Benjamin J |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function <it>in vivo</it>. In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c.</p> <p>Methods</p> <p>In order to understand how ovarian xenograft tumors may be growing and responding to anti-tumor therapeutics, we used genome-wide mRNA expression and DNA copy number measurements to identify key genes and pathways that may be critical for SKOV-3 xenograft tumor progression. We compared SKOV-3 xenografts treated with the ergocalciferol derived, MT19c, to untreated tumors collected at multiple time points. Cell viability assays were used to test the function of the PPARγ agonist, Rosiglitazone, on SKOV-3 cell growth.</p> <p>Results</p> <p>These data indicate that a number of known survival and growth pathways including Notch signaling and general apoptosis factors are differentially expressed in treated vs. untreated xenografts. As tumors grow, cell cycle and DNA replication genes show increased expression, consistent with faster growth. The steroid nuclear receptor, PPARγ, was significantly up-regulated in MT19c treated xenografts. Surprisingly, stimulation of PPARγ with Rosiglitazone reduced the efficacy of MT19c and cisplatin suggesting that PPARγ is regulating a survival pathway in SKOV-3 cells. To identify which genes may be important for tumor growth and treatment response, we observed that MT19c down-regulates some high copy number genes and stimulates expression of some low copy number genes suggesting that these genes are particularly important for SKOV-3 xenograft growth and survival.</p> <p>Conclusions</p> <p>We have characterized the time dependent responses of ovarian xenograft tumors to the vitamin D analog, MT19c. Our results suggest that PPARγ promotes survival for some ovarian tumor cells. We propose that a combination of regulated expression and copy number can identify genes that are likely important for chemotherapy response. Our findings suggest a new approach to identify candidate genes that are critical for anti-tumor therapy.</p> |
| first_indexed | 2024-04-13T01:01:23Z |
| format | Article |
| id | doaj.art-b20c8d95a675420f891e88386e50734d |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T01:01:23Z |
| publishDate | 2011-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-b20c8d95a675420f891e88386e50734d2022-12-22T03:09:28ZengBMCBMC Cancer1471-24072011-07-0111130810.1186/1471-2407-11-308Integrated genomics of ovarian xenograft tumor progression and chemotherapy responseRaphael Benjamin JSingh Rakesh KRitz AnnaKim Kyu KMiller Daniel HHillenmeyer SaraFischer AndrewStuckey AshleyBrard LaurentBrodsky Alexander S<p>Abstract</p> <p>Background</p> <p>Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function <it>in vivo</it>. In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c.</p> <p>Methods</p> <p>In order to understand how ovarian xenograft tumors may be growing and responding to anti-tumor therapeutics, we used genome-wide mRNA expression and DNA copy number measurements to identify key genes and pathways that may be critical for SKOV-3 xenograft tumor progression. We compared SKOV-3 xenografts treated with the ergocalciferol derived, MT19c, to untreated tumors collected at multiple time points. Cell viability assays were used to test the function of the PPARγ agonist, Rosiglitazone, on SKOV-3 cell growth.</p> <p>Results</p> <p>These data indicate that a number of known survival and growth pathways including Notch signaling and general apoptosis factors are differentially expressed in treated vs. untreated xenografts. As tumors grow, cell cycle and DNA replication genes show increased expression, consistent with faster growth. The steroid nuclear receptor, PPARγ, was significantly up-regulated in MT19c treated xenografts. Surprisingly, stimulation of PPARγ with Rosiglitazone reduced the efficacy of MT19c and cisplatin suggesting that PPARγ is regulating a survival pathway in SKOV-3 cells. To identify which genes may be important for tumor growth and treatment response, we observed that MT19c down-regulates some high copy number genes and stimulates expression of some low copy number genes suggesting that these genes are particularly important for SKOV-3 xenograft growth and survival.</p> <p>Conclusions</p> <p>We have characterized the time dependent responses of ovarian xenograft tumors to the vitamin D analog, MT19c. Our results suggest that PPARγ promotes survival for some ovarian tumor cells. We propose that a combination of regulated expression and copy number can identify genes that are likely important for chemotherapy response. Our findings suggest a new approach to identify candidate genes that are critical for anti-tumor therapy.</p>http://www.biomedcentral.com/1471-2407/11/308 |
| spellingShingle | Raphael Benjamin J Singh Rakesh K Ritz Anna Kim Kyu K Miller Daniel H Hillenmeyer Sara Fischer Andrew Stuckey Ashley Brard Laurent Brodsky Alexander S Integrated genomics of ovarian xenograft tumor progression and chemotherapy response BMC Cancer |
| title | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| title_full | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| title_fullStr | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| title_full_unstemmed | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| title_short | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| title_sort | integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| url | http://www.biomedcentral.com/1471-2407/11/308 |
| work_keys_str_mv | AT raphaelbenjaminj integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT singhrakeshk integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT ritzanna integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT kimkyuk integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT millerdanielh integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT hillenmeyersara integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT fischerandrew integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT stuckeyashley integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT brardlaurent integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse AT brodskyalexanders integratedgenomicsofovarianxenografttumorprogressionandchemotherapyresponse |